Stock Events

Stock Events

Novavax 

€8.54
1138
-€0.20-2.23% 06:04 Today

Statistics

Day High
8.54
Day Low
8.54
52W High
9.62
52W Low
5.48
Volume
0
Avg. Volume
24
Mkt Cap
1.41B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Dec 7
€1.61
Nov 7
€1.61
Oct 7
€1.61
Sep 7
€1.61
Aug 7
€1.61
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

5NovExpected
Q1 2026
Q2 2026
Next
-0.33
-0.24
-0.14
-0.05
Expected EPS
-0.1995088176
Actual EPS
N/A

Financials

41.04%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1BRevenue
412.27MNet Income

Analyst Ratings

6.83Average Price Target
The highest estimate is 6.83.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVV1.MU. It's not an investment recommendation.
Tesla
194
TSLA
Apple
183
AAPL
Microsoft
181
MSFT
Amazon
177
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap58.11B
Moderna is a direct competitor in the mRNA vaccine space, particularly for COVID-19, similar to Novavax's efforts in vaccine development.
Pfizer
PFE
Mkt Cap162.16B
Pfizer, in collaboration with BioNTech, developed a COVID-19 vaccine that competes directly with Novavax's COVID-19 vaccine.
BioNTech
BNTX
Mkt Cap26.06B
BioNTech partners with Pfizer for the COVID-19 vaccine, making it a direct competitor to Novavax in the vaccine market.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson developed a single-shot COVID-19 vaccine, competing in the same pandemic response market as Novavax.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca developed a COVID-19 vaccine using a different technology but competes in the same global vaccine market as Novavax.
Sanofi
SNY
Mkt Cap106.01B
Sanofi is working on COVID-19 vaccine candidates and influenza vaccines, positioning it as a competitor in the broader vaccine market.
GSK
GSK
Mkt Cap99.96B
GlaxoSmithKline, with its extensive vaccine portfolio and efforts in COVID-19 vaccine development, competes in the same space as Novavax.
Novavax
NVAX
Mkt Cap1.69B
Dynavax offers adjuvants for vaccines, making it a competitor in the broader vaccine development and enhancement market.

About

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Show more...
CEO
John Charles Jacobs
Employees
749
Country
United States
ISIN
US6700024010
WKN
000A2PKMZ

Listings

VI
AT
NVAX.VI
STU
DE
NVV1.STU
STU
DE
NVV.STU
MU
DE
NVV1.MU

0 Comments

Share your thoughts

FAQ

What is Novavax stock price today?▼
The current price of NVV1.MU is €8.54 EUR — it has decreased by -2.23% in the past 24 hours. Watch Novavax stock price performance more closely on the chart.
What is Novavax stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Novavax stocks are traded under the ticker NVV1.MU.
Is Novavax stock price growing?▼
NVV1.MU stock has fallen by -3.24% compared to the previous week, the month change is a +24.96% rise, over the last year Novavax has showed a +25.95% increase.
What is Novavax market cap?▼
Today Novavax has the market capitalization of 1.41B
When is the next Novavax earnings date?▼
Novavax is going to release the next earnings report on November 05, 2026.
What were Novavax earnings last quarter?▼
NVV1.MU earnings for the last quarter are -0.28 EUR per share, whereas the estimation was -0.33 EUR resulting in a +15.75% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Novavax revenue for the last year?▼
Novavax revenue for the last year amounts to 1B EUR.
What is Novavax net income for the last year?▼
NVV1.MU net income for the last year is 412.27M EUR.
Does Novavax pay dividends?▼
Yes, NVV1.MU dividends are paid monthly. The last dividend per share was 1.61 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Novavax have?▼
As of September 10, 2026, the company has 749 employees.
In which sector is Novavax located?▼
Novavax operates in the Health & Wellness sector.
When did Novavax complete a stock split?▼
The last stock split for Novavax was on May 10, 2019 with a ratio of 1:20.
Where is Novavax headquartered?▼
Novavax is headquartered in GAITHERSBURG, United States.